| Identification | Back Directory | [Name]
AVL-292 | [CAS]
1202757-89-8 | [Synonyms]
CC-292
CS-733
AVL-292
LMK-435
Spebrutinib
AVL-292 >=98%
CC-292,LMK-435
AVL 292 - CC 292
CC-292 (AVL-292)
AVL-292 USP/EP/BP
Spebrutinib (CC292
Spebrutinib (AVL-292)
AVL-292 (Spebrutinib)
Spebrutinib (CC-292, AVL-292)
CC-292; AVL292; AVL-292; AVL 292
CC-292;AVL292;AVL-292;AVL 292;SPEBRUTINIB
N-(3-((5-fluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide
N-(3-((5-fluoroethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide (AVL-292)
N-(3-((5-fluoro-2-((4-(2-methoxyethoxy)phenyl)amino)pyrimidin-4-yl)amino)phenyl)acrylamide
N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide
N-{3-[(5-Fluoro-2-{[4-(2-methoxyethoxy)phenyl]amino}pyrimidin-4-yl)amino]phenyl}prop-2-enamide
2-Propenamide, N-[3-[[5-fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-
N-[3-[[5-Fluoro-2-[[4-(2-methoxyethoxy)phenyl]amino]-4-pyrimidinyl]amino]phenyl]-2-propenamide AVL292 | [Molecular Formula]
C22H22FN5O3 | [MDL Number]
MFCD25976876 | [MOL File]
1202757-89-8.mol | [Molecular Weight]
423.44 |
| Chemical Properties | Back Directory | [density ]
1.322±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
≥21.15 mg/mL in DMSO; insoluble in H2O; ≥4.9 mg/mL in EtOH with gentle warming and ultrasonic | [form ]
solid | [pka]
13.22±0.70(Predicted) | [CAS DataBase Reference]
1202757-89-8 |
| Hazard Information | Back Directory | [Uses]
Bruton’s tyrosine kinase (BTK) is a non-receptor tyrosine kinase involved in signal transduction pathways regulating the proliferation, activation, and differentiation of B cells. AVL-292 is an orally available, selective, and irreversible inhibitor of BTK (IC50 = 0.5 nM in vitro in B cell lymphoma cell lines) that targets and covalently binds to BTK at cysteine-481, thereby preventing its activity. AVL-292 has been shown to inhibit osteoclast function and to reduce osteoclast-stimulated proliferation of multiple myeloma cells in animal models of rheumatoid arthritis and multiple sclerosis, both of which are diseases where B cells play an important role. In clinical trials, AVL-292 has demonstrated therapeutic significance in the treatment of both B cell-related cancers (e.g., non-Hodgkin’s lymphoma and B cell chronic lymphocytic leukemia) and autoimmune diseases (e.g., rheumatoid arthritis).[Cayman Chemical] | [target]
Btk | [storage]
Store at -20°C |
|
|